PEM-Seq

Creative Biogene CRISPR/Cas9 Platform provides a PEM-Seq service to assess off-target effect of CRISPR/Cas9 as well as on-target activity. At CRISPR/Cas9 Platform^CB, all projects are performed by skillful staff under the guide of experienced scientists. We are dedicated to assisting you and paving the way for your successful research with reliable services and products.

Since CRISPR/Cas9 technology was applied for genome engineering, it brings a revolutionary development of genome-editing technology. It provides an easier and faster way to do gene editing in different cells. However, its off-target cleavage is a major hinder for its clinical application. Unexpected cleavages in genome may induce serious side effects. Though most of the off-target cleavages are at low frequencies, it is important and required to assess the risk of off-targets.

Various high-throughput sequencing methods (in vivo or in vitro) are designed for identifying the off-target caused by CRISPR-Cas9. Primer-Extension-Mediated Sequencing (PEM-Seq) is a high-throughput sequencing method to fully assess the specificity of engineered nuclease as well as the editing ability. With this method, even chromosomal translocations and large deletions could be detected. Simultaneously, the on-target editing efficiency could be assessed. PEM-seq could sensitively detect CRISPR/Cas9 cutting sites and assess their editing efficiency by quantifying imperfect Cas9-induced DSB repair products. Compared to other methods, PEM-Seq provides a more comprehensive information for the editing events and help choosing better editing strategy.

Fig 1. Overview of PEM-Seq method¹

CRISPR/Cas9 Platform^CB provides a one-stop PEM-Seq service, including sample preparation, sequencing and data analysis. Once a project finished, we will provide a detailed reporter with experiment results and raw data to customers.

For more information, please contact us. We are waiting for your interest projects.

Related Services

Reference

Yin, J., Liu, M., Liu, Y. et al. Optimizing genome editing strategy by primer-extension-mediated sequencing. Cell Discov 5, 18 (2019).

For research use only. Not intended for any clinical use.

Inquiry